Todos os estudos
Inscrição por conviteFASE2INTERVENCIONISTA

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

This research is a continuation of an earlier study focusing on Myotonic Dystrophy Type 1 (DM1). Myotonic Dystrophy Type 1 is a condition that causes muscle weakness and other problems. Scientists want to see how safe a new medicine, called VX-670, is when taken for a longer period. They also want to check if it continues to help with the symptoms of DM1 and how the body handles the medicine over time. Only people who have already taken part in a specific previous study involving VX-670 can join this long-term follow-up research.

Em resumo

Status
Inscrição por convite
Fase
FASE2
Patrocinador
Vertex Pharmaceuticals Incorporada
Meta de inscrição
44
Iniciar
28 de abr de 2025
Conclusão estimada
30 Jan 2029

Sobre o que é este estudo?

This study is all about understanding a new medicine called VX-670, which is being developed for people living with Myotonic Dystrophy Type 1, often shortened to DM1. DM1 is a condition that affects muscles, causing them to gradually weaken and making everyday tasks harder. It can also impact other parts of the body.

The main goal of this particular research is to carefully watch what happens when people take VX-670 over a longer period. The researchers want to make sure it's safe and doesn't cause unexpected problems. They're also keen to see if the medicine continues to work well in managing the symptoms of DM1 and how the body processes it over time.

This study is essentially a follow-up for people who have already started treatment with VX-670 in a previous study. By continuing to gather information, doctors and scientists hope to learn more about how this potential new treatment could improve the lives of people with DM1 in the long run.

Pontos principais

  • This study is for people already taking the medicine VX-670 for Myotonic Dystrophy Type 1.
  • It aims to understand the long-term safety and effects of VX-670.
  • Participants must have completed a previous related study.
  • The study includes adults aged 18 and over, both men and women.
  • This is a Phase 2 study, focused on continued safety and how well the treatment works over time.

Quem pode ser elegível?

To join this study, there are some specific requirements. The most important one is that you must have already taken part in a previous study about the same medicine, VX-670. This previous study was called VX23-670-001.

There are also some things that would prevent you from taking part. For example, if you have any other serious health conditions that are outlined in the study plan, you might not be able to join. These conditions are carefully chosen to make sure the study is safe for everyone involved and that the results are clear.

Overall, the study is open to both men and women who are 18 years old or older. The research team will check all your details carefully to see if this study is right for you.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Did I already take part in the study called VX23-670-001?
  2. Tenho 18 anos ou mais?
  3. Do I have Myotonic Dystrophy Type 1 (DM1)?
  4. Do I have any other major health issues that might prevent me from joining?
  5. Have I discussed this study with my doctor?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you are eligible and agree to take part, your involvement would typically include regular visits to a clinic. During these visits, the study team would perform various assessments to check your health, monitor any side effects, and see how the medicine is working. This might involve physical examinations, blood tests, and questionnaires about your symptoms and how you are feeling. You would continue to take the study medicine, VX-670, as directed by the research team. The total duration of your participation would depend on the study's plan, but it's designed to look at the long-term effects of the medication.

Riscos e benefícios potenciais

Taking part in this study could potentially offer some benefits, such as continued access to a new experimental medicine (VX-670) and close monitoring of your health by medical professionals. However, as with any medicine, there are potential risks, including side effects from the treatment. The research team will explain all known risks to you. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Localizações (16)

  • St. Louis Children's Hospital - Neurology
    Código postal verificado
    St Louis, Estados Unidos
  • Wake Forest Univ School of Medicine - Neurology
    Código postal verificado
    Winston-Salem, Estados Unidos
  • Virginia Commonwealth University - Sanger Hall
    Código postal verificado
    Richmond, United States
  • Wesley Research Institute
    Código postal verificado
    Auchenflower, Austrália
  • Neuroscience Clinical Trials Unit, Alfred Brain
    Código postal verificado
    Melbourne, Austrália
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology
    Código postal verificado
    Leuven, Bélgica
  • Altasciences Montreal
    Código postal verificado
    Montreal, Canadá
  • Montreal Neurological Institute-Hospital
    Código postal verificado
    Montreal, Canadá
  • University of Ottawa
    Código postal verificado
    Ottawa, Canadá
  • Universite Laval - Neurology
    Código postal verificado
    Québec, Canada
  • Friedrich Baur Institute
    Código postal verificado
    Munique, Alemanha
  • Maastricht UMC
    Código postal verificado
    Maastricht, Países Baixos

Perguntas frequentes

What is Myotonic Dystrophy Type 1 (DM1)?

DM1 is a condition that causes muscles to weaken over time. It can also affect other parts of the body.

What is VX-670?

VX-670 is the name of the new medicine being tested in this study for DM1.

Which phase is this study in?

This study is in Phase 2, which means researchers are checking the medicine's safety and effectiveness in a larger group of people.

Can anyone with DM1 join this study?

No, you must have already taken part in a specific previous study about VX-670 to be eligible for this one.

Quanto tempo durará o estudo?

This is a 'long-term' study, meaning it will track participants over an extended period to monitor the medicine's effects over time.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study of Long-term Safety and Efficacy of VX-670 in Partic…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.